Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZVRA Stock Forecast 2026-2027
$12.96
Current Price
$772.04M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ZVRA Price Targets
+170.1%
To High Target of $35.00
+108.3%
To Median Target of $27.00
+62.0%
To Low Target of $21.00
ZVRA Price Momentum
-2.9%
1 Week Change
+2.8%
1 Month Change
+2.4%
1 Year Change
+44.6%
Year-to-Date Change
-13.8%
From 52W High of $15.04
+81.0%
From 52W Low of $7.16
📊 TOP ANALYST CALLS
Did ZVRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if KemPharm is one of their latest high-conviction picks.
Latest ZVRA Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ZVRA has a bullish consensus with a median price target of $27.00 (ranging from $21.00 to $35.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $12.96, the median forecast implies a 108.3% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZVRA Analyst Ratings
9
Buy
0
Hold
0
Sell
ZVRA Price Target Range
Low
$21.00
Average
$27.00
High
$35.00
Current: $12.96
Latest ZVRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZVRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $26.00 |
| Jun 11, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jun 10, 2026 | Maxim Group | Buy | Maintains | $N/A | |
| Jun 10, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Jun 9, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Jun 9, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jun 9, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Jun 8, 2026 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| May 8, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 16, 2026 | BTIG | Buy | Initiates | $N/A | |
| Nov 6, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 6, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Aug 13, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jul 10, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jul 2, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| May 14, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Mar 13, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 13, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 12, 2025 | Citizens Capital Markets | Market Outperform | Maintains | $N/A |
Zevra Therapeutics, Inc. (ZVRA) Competitors
The following stocks are similar to KemPharm based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zevra Therapeutics, Inc. (ZVRA) Financial Data
Zevra Therapeutics, Inc. has a market capitalization of $772.04M with a P/E ratio of 6.6x. The company generates $122.29M in trailing twelve-month revenue with a 101.6% profit margin.
Revenue growth is +77.5% quarter-over-quarter, while maintaining an operating margin of +24.4% and return on equity of +100.7%.
Valuation Metrics
Market Cap
$772.04M
Enterprise Value
$579.67M
P/E Ratio
6.6x
PEG Ratio
0.0x
Price/Sales
6.4x
Growth & Margins
Revenue Growth (YoY)
+77.5%
Gross Margin
+94.8%
Operating Margin
+24.4%
Net Margin
+101.6%
EPS Growth
+77.5%
Financial Health
Cash/Price Ratio
+26.2%
Current Ratio
4.9x
Debt/Equity
0.6x
ROE
+100.7%
ROA
+2.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zevra Therapeutics, Inc. (ZVRA) Business Model
About Zevra Therapeutics, Inc.
What They Do
Develops treatments for rare diseases.
Business Model
Zevra Therapeutics generates revenue by developing and commercializing therapies for rare neurological and sleep-related conditions, focusing on patient populations with limited treatment options. Additionally, the company earns royalty revenue from AZSTARYS, an ADHD treatment, through partnerships.
Additional Information
Founded in 2006 and headquartered in Celebration, Florida, Zevra operates in the health technology and pharmaceuticals industry. It emphasizes data-driven development and collaboration with the rare disease community to address underserved conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
61
CEO
Mr. Neil F. McFarlane
Country
United States
IPO Year
2021
Website
www.zevra.comZevra Therapeutics, Inc. (ZVRA) Latest News & Analysis
Latest News
Quick Summary
MIPLYFFA (arimoclomol) showed good tolerance in pediatric patients, with no new safety concerns reported, according to data in Molecular Genetics and Metabolism Reports.
Why It Matters
Positive safety data for MIPLYFFA in pediatric patients may boost investor confidence in the drug's market potential, potentially increasing stock value for the company involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
1 month ago
Quick Summary
Zevra Therapeutics announced that CMO Adrian Quartel will resign effective July 3, 2026, due to personal reasons but will consult until December 31, 2026, during the search for his successor.
Why It Matters
Leadership changes can impact company stability and strategy. Dr. Quartel's departure may affect investor confidence and the company's direction in rare disease therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zevra Therapeutics (NASDAQ: ZVRA) submitted a patent for its product MIPLYFFA to the FDA's Orange Book, securing patent protection until 2041.
Why It Matters
Zevra's patent submission for MIPLYFFA enhances its market position and potential revenue, protecting its product until 2041, which could attract investor interest and boost stock value.
Source: Proactive Investors
Market Sentiment:
Positive
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
1 month ago
Quick Summary
Zevra Therapeutics submitted a patent for MIPLYFFA® (arimoclomol) for Orange Book listing, with patent protection until 2041. A patent term extension is pending with the U.S. Patent Office.
Why It Matters
Patent protection until 2041 enhances MIPLYFFA's market exclusivity, potentially increasing Zevra's revenue and stability, crucial factors for investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zevra Therapeutics granted options for 33,000 shares to four new employees under its 2023 Employment Inducement Award Plan, with a four-year vesting schedule.
Why It Matters
Zevra Therapeutics is incentivizing new talent with stock options, which can enhance employee retention and align interests, potentially driving company growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) will present at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at 9:00 a.m. ET, focusing on therapies for rare diseases.
Why It Matters
Zevra Therapeutics' presentation at a major investor conference highlights its commitment to transparency and growth, potentially influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ZVRA Stock
What is Zevra Therapeutics, Inc.'s (ZVRA) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Zevra Therapeutics, Inc. (ZVRA) has a median price target of $27.00. The highest price target is $35.00 and the lowest is $21.00.
Is ZVRA stock a good investment in 2027?
According to current analyst ratings, ZVRA has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZVRA stock?
Wall Street analysts predict ZVRA stock could reach $27.00 in the next 12 months. This represents a 108.3% increase from the current price of $12.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zevra Therapeutics, Inc.'s business model?
Zevra Therapeutics generates revenue by developing and commercializing therapies for rare neurological and sleep-related conditions, focusing on patient populations with limited treatment options. Additionally, the company earns royalty revenue from AZSTARYS, an ADHD treatment, through partnerships.
What is the highest forecasted price for ZVRA Zevra Therapeutics, Inc.?
The highest price target for ZVRA is $35.00 from at , which represents a 170.1% increase from the current price of $12.96.
What is the lowest forecasted price for ZVRA Zevra Therapeutics, Inc.?
The lowest price target for ZVRA is $21.00 from at , which represents a 62.0% increase from the current price of $12.96.
What is the overall ZVRA consensus from analysts for Zevra Therapeutics, Inc.?
The overall analyst consensus for ZVRA is bullish. Out of 6 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are ZVRA stock price projections?
Stock price projections, including those for Zevra Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 6:26 PM UTC